Original Article
A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
N Engl J Med 1995; 332:1457-1463June 1, 1995
- Abstract
Background
We studied the effects of long-term treatment with interferon on histologic features of the liver and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis.
Methods
Consecutive patients who met the inclusion criteria were enrolled in the study. The diagnosis of chronic non-A, non-B hepatitis was established on the basis of the liver-biopsy findings and an abnormal serum alanine aminotransferase value (more than 1.5 times the normal value) for at least one year. All patients were treated for 6 months with 3 million units of interferon alfa-2b given subcutaneously three times a week and were then randomly assigned to the same treatment for an additional 12 months (group 1), a regimen of 1 million units three times a week for 12 months (group 2), or no further treatment (group 3). Patients in group 3 who had elevated serum alanine aminotransferase concentrations for three consecutive months underwent the initial regimen once again. Follow-up continued for two years after the discontinuation of treatment. Histologic improvement was defined as a decrease of at least one point in the score for necroinflammatory activity (0, no activity; 1, mild; 2, moderate; or 3, severe) between the first liver biopsy and a biopsy performed at 18 months.
Results
Of the 329 patients initially treated, 303 were randomized: 103 to group 1, 101 to group 2, and 99 to group 3. Of the 286 patients tested, 252 (88.1 percent) had antibodies to hepatitis C virus. In an intention-to-treat analysis, 46 of the patients in group 1 (44.7 percent) had normal serum alanine aminotransferase values at 18 months, as compared with 27 of the patients in group 2 (26.7 percent, P = 0.008) and 30 of those in group 3 (30.3 percent, P = 0.04). Between 19 and 42 months, 23 of the patients in group 1 (22.3 percent) continued to have normal serum alanine aminotransferase values (measured every 6 months), as compared with 10 of the patients in group 2 (9.9 percent, P = 0.02) and 8 of those in group 3 (8.1 percent, P = 0.005). Among the 176 patients with repeated liver biopsies at 18 months, more patients in group 1 had improved histologic-activity scores (69.6 percent) than in group 2 (47.6 percent, P = 0.02) or group 3 (38.6 percent, P<0.001).
Conclusions
Among patients with chronic non-A, non-B hepatitis, a regimen of 3 million units of interferon alfa-2b given three times a week for 18 months produced better histologic findings and serum alanine aminotransferase values than regimens involving a lower dose or a shorter duration of treatment.
Media in This Article
Figure 1
Histologic Improvement at 18 Months in the Three Treatment Groups, According to the Serum Alanine Aminotransferase Response at 6 Months (Upper Panel) and 18 Months (Lower Panel).Table 1
Base-Line Characteristics of 303 Patients with Non-A, Non-B Hepatitis Treated with Interferon Alfa-2b.Article Activity
- Article
Interferon alfa is effective in reducing serum alanine aminotransferase concentrations during treatment and, to a lesser extent, during the year after treatment in patients with chronic hepatitis C virus (HCV) infection.1 Liver-biopsy findings may be more accurate than serum alanine aminotransferase values as a surrogate marker of the response to therapy. Among patients with chronic HCV infection, morbidity and mortality occur only in those with severe chronic active hepatitis or cirrhosis. In patients with chronic viral hepatitis, portal and lobular necroinflammatory lesions may be precursors of cirrhosis.2 It is reasonable to assume that a reduction in inflammation and necrosis in patients with cirrhosis may reduce mortality.
There is no clear evidence that serum alanine aminotransferase values can accurately predict the liver-biopsy findings in patients with HCV infection, whether or not they receive treatment with interferon. Nevertheless, evaluation of the efficacy of treatment and identification of possible prognostic factors are often based on serum alanine aminotransferase measurements alone.
We studied the effect of three interferon alfa-2b regimens over an 18-month period on liver-biopsy findings and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis. After the treatment period, follow-up continued for two years. We also studied the relation between changes in liver-biopsy findings and changes in serum alanine aminotransferase concentrations.
Methods
Patients
Patients enrolled in the study had a diagnosis of chronic non-A, non-B hepatitis established on the basis of liver-biopsy findings and abnormal serum alanine aminotransferase values (higher than 1.5 times the normal value) for at least one year. Patients were excluded if they met any of the following criteria: age under 18 years, a positive test for serum hepatitis B surface antigen, current drug addiction, a positive test for serum antibodies to the human immunodeficiency virus, a liver biopsy performed more than six months earlier, major iron deposits in the liver, pregnancy or absence of contraceptive use in women of childbearing age, a severe associated disease or decompensated cirrhosis, or failure to provide written informed consent. The study was conducted in 39 centers. Consecutive patients who met the eligibility criteria were enrolled between 1989 and 1991.
Treatment
All patients were treated for six months with interferon alfa-2b (Intron A, Schering, Kenilworth, N.J.) in a dose of 3 million units administered subcutaneously three times a week. After six months, the patients were randomly assigned to one of three groups. The assignments were made with the use of sealed envelopes, without knowledge of any clinical or biologic data. Patients in group 1 received 3 million units of interferon three times a week for an additional 12 months, or a total of 18 months. Patients in group 2 received 1 million units of interferon three times a week for an additional 12 months. Patients in group 3 received no further treatment with interferon, unless their serum alanine aminotransferase concentrations were above the upper limit of normal for 3 consecutive months, in which case they received 3 million units of interferon three times a week through the 18th month after the initial treatment.
Liver-Biopsy Studies
Liver-biopsy specimens obtained at the time of enrollment and at 18 months were assessed independently by two of us, who were not aware of the timing of the biopsy or of any clinical or biochemical data. The specimens were evaluated according to a previously validated scoring system,3 which includes 27 semiquantitatively scored items. The last item assesses necroinflammatory activity (0, no activity; 1, mild; 2, moderate; or 3, severe), taking into account the severity of portal and lobular necroinflammatory lesions. Histologic improvement was defined as a decrease of at least one point in the score for histologic activity between the first and second liver biopsies.
Virologic Data
At the beginning of the study, data on antibodies to HCV were not available, and assays were performed during follow-up. For the molecular studies, either stored frozen serum samples obtained before or after enrollment or fresh samples were used. Polymerase-chain-reaction (PCR) studies were performed with the Amplicor Roche Diagnostic System (Hoffmann–LaRoche, Basel, Switzerland), quantification by branched DNA was performed with Amplex Chiron (Chiron, Emeryville, Calif.), and genotyping was performed with PCR and fluorescent competitive oligonucleotide primers, a technique that has recently been validated.4
Statistical Analysis
The main end point chosen to calculate the required sample size was the anticipated serum alanine aminotransferase response between 7 and 18 months after the initiation of treatment. It was calculated that 100 patients per group were needed to detect a difference of 20 percent in the proportion of patients with responses, at least between groups 1 and 2 (40 and 20 percent, respectively), with an alpha error of 5 percent and a beta error of 10 percent.
Five end points involving serum alanine aminotransferase measurements were used: a complete response to interferon at 6 months (a normal serum alanine aminotransferase concentration at the 5th and 6th months), at 18 months (a normal concentration at the 17th and 18th months), and between the 7th and 18th months (a normal concentration each month); a partial or complete response at 3 months (a serum alanine aminotransferase concentration lower than twice the upper limit of the normal value); and a complete response sustained throughout the 2 years after the end of treatment (a normal serum alanine aminotransferase concentration every 6 months).
Statistical methods (two-tailed) included the chi-square test, Fisher's exact test, Student's t-test, and the Mann–Whitney nonparametric test.5 Regression analysis was used to assess the independent effect of treatment on potential prognostic factors. Since there was a trend toward a better serum alanine aminotransferase response in group 1 at six months (when all groups had received the same treatment), separate logistic-regression analyses were performed to control for this difference. All comparisons of serum alanine aminotransferase values were performed twice: according to the intention-to-treat method and according to a per-protocol strategy. In the intention-to-treat analysis, no patients were excluded after randomization, even in the case of noncompliance or missing data. In the per-protocol analysis, patients with missing data were excluded. When two consecutive serum alanine aminotransferase values were missing, the patient was considered not to have had a response. To evaluate the possibility of bias, the patients who underwent two liver biopsies were compared with the patients who underwent only one, with the use of univariate and multivariate techniques (data not shown).
All patients provided written informed consent before randomization. The protocol was approved by the ethics committee of Paris Sud University.
Results
Of the 329 patients enrolled in the study, 20 stopped treatment during the first six months because of adverse events, 3 were lost to follow-up, 2 declined to undergo randomization, and 1 died of hepatocellular carcinoma. At six months, the remaining 303 patients were randomly assigned to one of the three groups; 103 were assigned to group 1, 101 to group 2, and 99 to group 3.
There were no significant differences among the groups at the beginning of the study (Table 1Table 1
Base-Line Characteristics of 303 Patients with Non-A, Non-B Hepatitis Treated with Interferon Alfa-2b.). Tests for serum HCV antibodies were performed with the enzyme-linked immunosorbent assay (first or second generation) in 286 patients; 252 (88.1 percent) had HCV antibodies.Compliance with Treatment and Protocol
In group 1, 31 patients stopped treatment: 19 because of adverse events or the development of other diseases, 9 because they did not wish to continue with the treatment, and 3 because their physicians did not follow the protocol. In group 2, 22 patients stopped treatment: 15 because of adverse events or the development of other diseases and 7 because they did not wish to continue. In group 3, 46 patients followed the protocol; 12, including 6 with complete and sustained biologic responses, were not retreated with interferon because their serum alanine aminotransferase concentrations were not elevated for three consecutive months. In 4 of the 34 patients who were retreated according to the protocol, retreatment was stopped because of adverse events. The protocol was not followed for 53 of the patients in group 3; in 46 patients who had elevated serum alanine aminotransferase concentrations for three consecutive months, treatment was not restarted, mainly because the patients had had adverse events during the initial treatment and therefore declined further treatment; in 6 patients, the initial treatment was not stopped at six months; and in 1 patient, treatment was restarted despite normal serum alanine aminotransferase concentrations.
The mean number of missing serum alanine aminotransferase values per patient was 0.5 during the first 6 months and 3.3 between the 7th and 18th months, with no differences among the three groups. During the two-year follow-up period after treatment, no serum alanine aminotransferase values were available for 37 patients in group 1, 27 in group 2, and 41 in group 3.
Serum Alanine Aminotransferase Concentrations and Virologic Responses
In group 1, as compared with groups 2 and 3, there was a significant increase in the percentage of patients with complete serum alanine aminotransferase responses at 18 months, between 7 and 18 months, and during the 2 years after treatment (Table 2Table 2
Normal Serum Alanine Aminotransferase Concentrations (Intention-to-Treat Analysis), Disappearance of Serum Hepatitis C Virus, and Residual Viremia.). The results of the per-protocol analyses were similar (data not shown). Viral data were retrospectively investigated for 100 patients. A total of 210 HCV PCR analyses and 135 quantifications of branched DNA were performed in the 100 patients, with 51 quantifications performed before treatment and 84 after treatment. Genotypes were identified in 58 patients. As compared with the patients in groups 2 and 3, those in group 1 were more likely to have negative results on HCV PCR analyses after treatment and to have lower quantities of virus as measured by the branched-DNA technique (Table 2).Histologic Responses
Of the 103 patients in group 1, 56 underwent liver biopsies at 18 months, as did 63 of the 101 patients in group 2 and 57 of the 99 patients in group 3. The percentage of patients in group 1 with histologic-activity scores that improved by at least one grade was 69.6 percent (39 of 56), as compared with 47.6 percent in group 2 (30 of 63 patients; odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.4; P = 0.02) and 38.6 percent in group 3 (22 of 57 patients; odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.9; P<0.001). A logistic-regression analysis that took into account the serum alanine aminotransferase response at six months showed that the patients in group 1 had stronger histologic responses than the patients in group 2 (odds ratio for an improvement in histologic-activity score by at least one grade, 2.4; 95 percent confidence interval, 1.1 to 5.3; P = 0.03) or those in group 3 (odds ratio, 3.7; 95 percent confidence interval, 1.7 to 8.0; P = 0.002).
Data on histologic changes with treatment are shown in Table 3Table 3
Changes in Histologic Scores, According to Treatment Group.. Patients in group 1 were significantly more likely than those in either group 2 or group 3 to have improvement in portal inflammation or piecemeal necrosis.Among the 132 patients without evidence of cirrhosis on the first liver biopsy, the incidence of cirrhosis throughout 18 months of follow-up was 6.8 percent in group 1 (3 of 44), as compared with 13.6 percent in group 2 (6 of 44, P = 0.24) and 15.9 percent in group 3 (7 of 44, P = 0.18).
Correlation between Histologic and Serum Alanine Aminotransferase Responses
The percentages of patients with histologic improvement at 18 months, according to the serum alanine aminotransferase responses at 6 and 18 months, are shown in Figure 1Figure 1
Histologic Improvement at 18 Months in the Three Treatment Groups, According to the Serum Alanine Aminotransferase Response at 6 Months (Upper Panel) and 18 Months (Lower Panel).. Sixty-one percent of the patients randomly assigned to group 1 had histologic improvement despite abnormal serum alanine aminotransferase concentrations at 6 months or at 18 months.Cirrhosis, age, and the initial serum γ-glutamyltransferase value were not associated with histologic responses in either univariate or multivariate analyses (data not shown). Genotype 1b was associated with a lower rate of histologic responses. Eight of 26 patients (30.8 percent) with genotype 1b had an improved histologic-activity score, as compared with 18 of 30 patients (60.0 percent) who did not have genotype 1b (P = 0.03). Among the patients with genotype 1b, 4 of 6 in group 1, 4 of 10 in group 2, and none of 10 in group 3 had histologic improvement (P = 0.008 by Fisher's exact test, two-tailed). Genotype 1b was associated with higher mean (±SE) levels of viremia both before treatment (40±8×105 equivalent viral copies per milliliter in 20 patients with genotype 1b vs. 19±5×105 in 21 patients without genotype 1b, P = 0.03) and after treatment (49±12×105 equivalent viral copies per milliliter in 24 patients with genotype 1b vs. 37±14×105 in 27 patients without genotype 1b, P = 0.04). Among the 80 patients from whom serum samples were collected after treatment, the mean level of viremia was significantly lower in the group of 40 patients with histologic improvement (18±9×105 equivalent viral copies per milliliter) than in the group of 40 without histologic improvement (34±8×105 equivalent viral copies per milliliter, P = 0.003).
Adverse Events
Adverse events of grade 3 or 4 in severity, according to the classification of the World Health Organization,7 were documented. For clinical events, grade 3 is defined as severe, and grade 4 as very severe. Grade 3 neutropenia is defined as less than 900 leukocytes per cubic millimeter, and grade 3 thrombocytopenia as less than 49,000 platelets per cubic millimeter. Adverse events of grade 3 or 4 occurred in 35 percent, 30 percent, and 31 percent of the patients in groups 1, 2, and 3, respectively, during the initial 18 months. From 7 to 18 months, the incidence of adverse events was 11, 6, and 7 percent in groups 1, 2, and 3, respectively. The differences among the groups were not significant. The most frequent adverse events were asthenia (in 50 percent of the patients), neutropenia (in 20 percent), myalgia (in 20 percent), headache (in 16 percent), an influenza-like syndrome (in 13 percent), thrombocytopenia (in 10 percent), and depression (in 9 percent). Some patients had more than one adverse event.
Discussion
The patients were followed for an additional 24 months after the discontinuation of treatment with interferon alfa-2b. Those treated for 18 months with 3 million units three times a week continued to have serum alanine aminotransferase and virologic responses. Histologic responses at 18 months were assessed in only 176 of the 303 randomized patients. Because the clinical and biologic findings did not differ according to whether the patients had one or two biopsies, bias due to the small number of patients assessed was unlikely. Liver-biopsy specimens were assessed in a blinded fashion, with a scoring system that had previously been validated.3 The histologic-activity score, which was the main end point, has been shown to be a better scoring system than the Knodell activity index, in terms of intraobserver and interobserver variation.8 The score we used did not include an assessment of liver fibrosis, which differs from necroinflammatory activity in terms of severity and responsiveness to treatment.6
None of the patients in group 1 had severe chronic active hepatitis at the second liver biopsy. The greater improvement in piecemeal necrosis and total inflammation in group 1 and the lower incidence of cirrhosis during follow-up suggest that the interferon regimen used in this group can sometimes prevent cirrhosis. It is also noteworthy that some patients with cirrhosis initially also had substantial histologic improvement. Although the diagnosis of cirrhosis is highly concordant among pathologists,3 sampling variability can affect its recognition. A future trial might test the hypothesis that continuous treatment with interferon can significantly reduce the incidence of cirrhosis in patients with chronic non-A, non-B hepatitis.
Serum alanine aminotransferase responses were significantly associated with histologic improvement, but we do not believe this association was strong enough to justify its use in clinical practice. Serum alanine aminotransferase measurements, even when repeated, were inaccurate in predicting the presence or absence of histologic improvement. We believe a repeated liver biopsy is required to assess the efficacy of treatment with interferon. In our study, it would have been a mistake to stop treatment in patients without a serum alanine aminotransferase response at six months. Indeed, a total of 61 percent of the patients without responses at 6 months (32 of 52) had improved histologic findings at 18 months, and the results were similar for patients without responses at 3 months (data not shown). These findings do not support the recommendations for treatment with interferon in the United States and in France, which suggest that interferon may be discontinued if there is no response after 16 weeks.9,10 Similarly, we do not believe the absence of a serum alanine aminotransferase response between 7 and 18 months is a reliable predictor that continued treatment will not be beneficial.
Several previously identified factors were significantly associated with the serum alanine aminotransferase response, including age, the presence of cirrhosis, and the initial serum γ-glutamyltransferase value. None of these factors, however, were associated with histologic improvement in univariate or multivariate analyses. These differences were not related to a potential bias in the selection of patients who underwent two biopsies, since the discrepancy persisted even when the analysis of factors related to the serum alanine aminotransferase responses was restricted to patients with two biopsies. Therefore, we do not believe that the selection of patients for treatment with interferon should be based on these factors.
Genotype and viremia were assessed retrospectively, and the findings should therefore be interpreted with caution. Since genotypes were, in part, determined retrospectively in samples obtained after treatment, data on genotypes were available for fewer patients in group 1 than in the other groups, because the PCR results were more often negative in the patients in group 1. Before and after treatment, genotype 1b was associated with a higher level of viremia than were other genotypes, but it was not possible to estimate whether these two factors were independently correlated with the serum alanine aminotransferase or histologic response. For example, patients with genotype 1b were on average 10 years older than those without genotype 1b (P = 0.006), and 62 percent of the patients with genotype 1b had cirrhosis, as compared with 30 percent of the patients without this genotype (P = 0.02). Nevertheless, among the patients with genotype 1b and two liver biopsies, histologic improvement was greater in group 1 than in the other groups.
We found that patients with histologic improvement at 18 months had about 50 percent less viremia during the 2 years of follow-up after treatment than the patients without improvement at 18 months. The greater efficacy of long-term treatment with interferon, as compared with a shorter duration of treatment or a lower dose of the drug, may be explained by the reduction or eradication of HCV viremia.
Supported by grants from the Association pour la Recherche sur le Cancer, the Direction des Hôpitaux, the Délégation à la Recherche Clinique, and Schering–Plough.
We are indebted to Jean Cougnard for statistical expertise and to Sandrine Juillard for assistance in the preparation of the manuscript.
Source Information
From the Service d'Hépato-Gastroentérologie, Hôpital Antoine Béclère, Clamart (T.P., J.C.C.); the Service d'Anatomie Pathologique, Hôpital de Bicêtre, Bicêtre (P.B.); Centre National de la Recherche Scientifique, Unité de Recherche Associée 1484, Paris (T.P., P.B., P.M., M.S., J.M.C., M.V.); Institut Pasteur, Lyons (M.C.); Schering–Plough Laboratories, Levallois (C.L.); the Services d'Hépato-Gastroentérologie Hôpital Hotel Dieu, Lyons (C.T.); Hôpital du Haut Lévèque, Pessac (P.C.); Hôpital Régional de Toulouse, Toulouse (J.L.P.); and Hôpital Américain de Paris, Neuilly (M.V., J.M.C.) — all in France.
Address reprint requests to Dr. Poynard at the Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié Salpétrière, 47-83 Boulevard de l'Hôpital, 75651 Paris CEDEX 13, France.
Members of the Multicenter Study Group are listed in the Appendix.
Appendix
The Multicenter Study Group included the following investigators: Lyons: J. Desbaumes, C. Trepo, and P. Paliard; Paris Pitié Salpétrière: P. Opolon, D. Valla, and F. Lunel; Paris Saint Antoine: R. Poupon, T. Andreani, J.D. Grange, Y. Calmus, and E. Froguel; Paris Saint Louis: X. Abensour and J.C. Rambaud; Paris Laennec: C. Brechot, S. Pol, and P. Berthelot; Paris Bichat: G. Cadiot; Bordeaux: P. Bernard, P. Couzigou, and A. Quinton; Toulouse: J.L. Payen and J.P. Pascal; Clamart: T. Poynard, P. Mathurin, and J.C. Chaput; Marseilles: A. Gauthier, M. Antoni, J. Sahel, and F. Klotz; Nice: J. Delmont, J.G. Fuzibet, P. Dujardin, A. Tran, P. Rampal, and C. Grimaldi; Toulon: X. Moreau and L. Aubert; Besançon: J.P. Miguet and A. Franza; Tours: Y. Bacq and E.H. Metman; Bobigny: D. Roulot; Grenoble: J.P. Zarski; Strasbourg: D. Vetter and M. Doffoel; Montpellier: M. Veyrac; Clichy: P. Marcellin, J.P. Benhamou, and M. Pouteau; Bondy: M. Beaugrand; Angers: P. Cales; Montauban: D. Grasset; Saint Etienne: H. Coppere; Nancy: M.A. Bigard; Versailles: J. Andrieu and J. Doll; Limoges: B. Pillegand; Corbeil: D. Constantini; Dijon: P. Hillon; Cannes: C. Gueyffier; and Compiègne: J.C. Barbare. Pathologists: P. Bedossa (Bicêtre) and M. Chevallier (Lyons); Schering–Plough: J. Cougnard and C. Lemonnier; molecular biologists: M. Sajus, M. Olivi, J.M. Costa, and M. Vidaud (CNRS URA 1484 Paris, Hôpital Américain de Paris).
- References
References
1
Tine F ,Magrin S ,Craxi A ,Pagliaro L . Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-199
CrossRef | Web of Science | Medline2
Cooksley WG ,Bradbear RA ,Robinson W , et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6:345-348
CrossRef | Web of Science | Medline3
The French Metavir Cooperative Study Group
CrossRef | Web of Science | Medline4
Sajus M ,Olivi M ,Vidaud M , et al. Analysis of genotypes by a fluorescent competitive oligonucleotide priming PCR (COP PCR):AASLD Chicago 1994. Hepatology 1994;20:244a-244a abstract.
Web of Science5
Dixon WG, ed. BMDP statistical software manual. Vol. 1, part 2. Los Angeles: BMDP Statistical Software, 1991.
6
Knodell RG ,Ishak KG ,Black WC , et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
CrossRef | Web of Science | Medline7
Miller AB ,Hoogstraten B ,Staquet M ,Winkler A . Reporting results of cancer treatment. Cancer 1981;47:207-214
CrossRef | Web of Science | Medline8
Scheuer PJ . Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374
CrossRef | Web of Science | Medline9
Physician's desk reference. 49th ed. Montvale, N.J.: Medical Economics, 1995:2266.
10
Vidal 1995. 71st ed. Paris: Editions Vidal, 1995:757.
- Citing Articles (171)
Citing Articles
1
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. Hepatitis C. , 582-652.
CrossRef2
Sirio Fiorino, Carmela Cursaro, Stefania Lorenzini, Elisabetta Loggi, Lucia Brodosi, Laura Cattani, Andrea Cuppini, Mauro Bernardi, Pietro Andreone. (2011) The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. Italian Journal of Medicine 5:2, 82-89
CrossRef3
T. Yoshida, M. Kondoh, M. Ojima, H. Mizuguchi, Y. Yamagishi, N. Sakamoto, K. Yagi. (2011) Adenovirus vector-mediated assay system for hepatitis C virus replication. Nucleic Acids Research 39:10, e64-e64
CrossRef4
Sajid Ali, Ijaz Ali, Sadiq Azam, Bashir Ahmad. (2011) Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Virology Journal 8:1, 193
CrossRef5
Harald Farnik, Christian M. Lange, Christoph Sarrazin, Bernd Kronenberger, Stefan Zeuzem, Eva Herrmann. (2010) Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 8:10, 884-890
CrossRef6
Nazish Bostan, Tariq Mahmood. (2010) An overview about hepatitis C: A devastating virus. Critical Reviews in Microbiology 36:2, 91-133
CrossRef7
Andrew Aronsohn, Nancy Reau. (2009) Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 43:7, 661-671
CrossRef8
Yu Du, Hong Tian, Xiang-Dong Gao, Wen-Bing Yao. (2008) Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-α (PEG-CIFN) in rhesus monkeys. Biopharmaceutics & Drug Disposition 29:8, 481-484
CrossRef9
Shintaro Abe, Ryoichi Narita, Toru Matsuhashi, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2008) Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 20:5, 373-378
CrossRef10
Murat Gürsoy, G. Gür, H. Arslan, N. Özdemir, S. Boyacıogˇlu. (2008) Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. Journal of Viral Hepatitis 8:1, 70
CrossRef11
T. Thévenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, T. Poynard. (2008) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. Journal of Viral Hepatitis 8:1, 48
CrossRef12
Ke-Qin Hu, John M. Vierling, Allan G. Redeker. (2008) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis 8:1, 1
CrossRef13
Brian L. Pearlman, Carole Ehleben, Sophia Saifee. (2007) Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1
infected slow responders. Hepatology 46:6, 1688-1694
CrossRef14
Nyingi Kemmer, Guy W. Neff. (2007) Managing chronic hepatitis C in the difficult-to-treat patient. Liver International 27:10, 1297-1310
CrossRef15
Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton. (2007) The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery 6:12, 991-1000
CrossRef16
Tomoyoshi Ohno, Noboru Hirashima, Etsuro Orito, Izumi Hasegawa, Kei Fujiwara, Kiyoaki Itoh, Atsushi Ozasa, Noboru Shinkai, Yasuhito Tanaka, Takanobu Kato, Ryuzo Ueda, Kenji Sakakibara. (2007) Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. Hepatology Research 37:4, 276-285
CrossRef17
Jun Yang, Anto Satriyo Nugroho, Kazunobu Yamauchi, Kentaro Yoshioka, Jiang Zheng, Kai Wang, Ken Kato, Susumu Kuroyanagi, Akira Iwata. (2007) Efficacy of Interferon Treatment for Chronic Hepatitis C Predicted by Feature Subset Selection and Support Vector Machine. Journal of Medical Systems 31:2, 117-123
CrossRef18
José M. Sánchez–Tapias, Moisés Diago, Pedro Escartín, Jaime Enríquez, Manuel Romero–Gómez, Rafael Bárcena, Javier Crespo, Raúl Andrade, Eva Martínez–Bauer, Ramón Pérez, Milagros Testillano, Ramón Planas, Ricard Solá, Manuel García–Bengoechea, Javier Garcia–Samaniego, Miguel Muñoz–Sánchez, Ricardo Moreno–Otero. (2006) Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology 131:2, 451-460
CrossRef19
Gil Weitzman, Ira Jacobson. (2006) Peginterferon α-2b in the treatment of hepatitis C. Future Virology 1:3, 279-292
CrossRef20
Thomas Berg, Michael von Wagner, Samer Nasser, Christoph Sarrazin, Tobias Heintges, Tilman Gerlach, Peter Buggisch, Tobias Goeser, Jens Rasenack, Gerd R. Pape, Wolfgang E. Schmidt, Birgit Kallinowski, Hartwig Klinker, Ulrich Spengler, Peter Martus, Ulrich Alshuth, Stefan Zeuzem. (2006) Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology 130:4, 1086-1097
CrossRef21
Amrita Sethi, Mitchell L. Shiffman. (2006) Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response. Infectious Disease Clinics of North America 20:1, 115-135
CrossRef22
Shintaro Abe, Ryoichi Narita, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2006) Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:1, 308-312
CrossRef23
2006. Interferon alfa. , 1793-1831.
CrossRef24
Chuan-Qing Wang, Yuan Li, Steven D. Douglas, Xu Wang, David S. Metzger, Ting Zhang, Wen-Zhe Ho. (2005) Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. The American Journal of Pathology 167:5, 1333-1340
CrossRef25
KOSEI HAMANO, NAOYA SAKAMOTO, NOBUYUKI ENOMOTO, NAMIKI IZUMI, YASUHIRO ASAHINA, MASAYUKI KUROSAKI, ERI UEDA, YOKO TANABE, SHINYA MAEKAWA, JUN ITAKURA, HIDEKI WATANABE, SEI KAKINUMA, MAMORU WATANABE. (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. Journal of Gastroenterology and Hepatology 20:9, 1401-1409
CrossRef26
M. F. Donato, C. Degott, E. Arosio, M. Martinot, V. Monti, A. Morabito, P. Marcellin, M. Colombo. (2005) Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 12:5, 499-506
CrossRef27
J. K. Lim, D. Wooten, R. Siegel, R. C. Cheung. (2005) Amantadine in treatment of chronic hepatitis C virus infection?. Journal of Viral Hepatitis 12:5, 445-455
CrossRef28
Graham R. Foster, Abid R. Suddle. (2005) Treatment of HCV infection with pegylated interferons. Current Hepatitis Reports 4:2, 49-55
CrossRef29
Takaji WAKITA. (2005) Kanzo 46:12, 691-702
CrossRef30
Charles L Raison, Marina Demetrashvili, Lucile Capuron, Andrew H Miller. (2005) Neuropsychiatric Adverse Effects of Interferon-??. CNS Drugs 19:2, 105-123
CrossRef31
T. Barry Kelleher, Nezam H. Afdhal. (2005) Maintenance therapy for chronic hepatitis C. Current Gastroenterology Reports 7:1, 50-53
CrossRef32
Paul J. Pockros, Robert Carithers, Paul Desmond, Daniel Dhumeaux, Michael W. Fried, Patrick Marcellin, Mitchell L. Shiffman, Gerald Minuk, K. Rajender Reddy, Robert W. Reindollar, Amy Lin, Michael J. Brunda, . (2004) Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial. The American Journal of Gastroenterology 99:7, 1298-1305
CrossRef33
N. Brau. (2004) Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 11:3, 191-197
CrossRef34
Brett D. Kalmowitz, Nezam H. Afdhal. (2004) Maintenance therapies for hepatitis C. Current Hepatitis Reports 3:1, 23-29
CrossRef35
Yasuji Arase, Kenji Ikeda, Akihito Tsubota, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada. (2004) Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection. Intervirology 47:6, 355-361
CrossRef36
Edna Strauss, Hoel Sette Junior. (2003) Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration. Liver International 23:6, 410-412
CrossRef37
R. Perez, M. Jimenez, J. Crespo, M. Diago, J. Enriquez, P. Vaquero, R. Sola, J. L. Olcoz, M. Romero, J. Salmeron, Ma I. Blanco, Ma Ona, S. Melon, L. Rodrigo, . (2003) Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. Journal of Viral Hepatitis 10:6, 437-445
CrossRef38
Wolfgang Vogel. (2003) Peginterferon-α 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 1:3, 423-431
CrossRef39
Yuan Li, Ting Zhang, Steven D. Douglas, Jian-Ping Lai, Wei-Dong Xiao, David E. Pleasure, Wen-Zhe Ho. (2003) Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. The American Journal of Pathology 163:3, 1167-1175
CrossRef40
Tomitsune Kitagami, Kiyofumi Yamada, Hideki Miura, Ryo Hashimoto, Toshitaka Nabeshima, Tatsurou Ohta. (2003) Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood–brain barrier. Brain Research 978:1-2, 104-114
CrossRef41
J. M. Vrolijk, F. C. Bekkering, J. T. Brouwer, B. E. Hansen, S. W. Schalm. (2003) High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. Journal of Viral Hepatitis 10:3, 205-209
CrossRef42
Zsófia Müller, Judith Deák, R.Stefan Ross, Elisabeth Nagy, László Kovács, M Roggendorf, Harald H Kessler. (2003) Hepatitis C virus genotypes in Hungarian and Austrian patients with chronic hepatitis C. Journal of Clinical Virology 26:3, 295-300
CrossRef43
Mitchell L. Shiffman. (2003) Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?. Current Hepatitis Reports 2:1, 17-23
CrossRef44
Mohammad Abdelrahman, Ali Rafi, Reda Ghacha, Ayman Karkar. (2003) HCV Induced Renal Disease. Renal Failure 25:3, 331-339
CrossRef45
Gloria Taliani, Maria Concetta Badolato, Giovanni Nigro, Mara Biasin, Vieri Boddi, Caterina Pasquazzi, Mario Clerici. (2002) Serum Concentration of γGT Is a Surrogate Marker of Hepatic TNF-α mRNA Expression in Chronic Hepatitis C. Clinical Immunology 105:3, 279-285
CrossRef46
Philippe Casassus, Nadine Caillat-Vigneron, Antoine Martin, Jeanne Simon, Valerie Gallais, Patrice Beaudry, Virginie Eclache, Liliane Laroche, Pierre Lortholary, Martine Raphael, Loic Guillevin, Olivier Lortholary. (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. British Journal of Haematology 119:4, 1090-1097
CrossRef47
Svetlozar N. Natov, Brian J. G. Pereira. (2002) Management of Hepatitis C Infection in Renal Transplant Recipients. American Journal of Transplantation 2:6, 483-490
CrossRef48
Robert P Myers, Corinne Regimbeau, Thierry Thevenot, Vincent Leroy, Philippe Mathurin, Pierre Opolon, Jean Pierre Zarski, Thierry Poynard, Robert P Myers. 2002. Interferon for interferon naive patients with chronic hepatitis C. .
CrossRef49
Paul J Pockros. (2002) Developments in the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs 11:4, 515-528
CrossRef50
NANCY WY LEUNG. (2002) Management of viral hepatitis C. Journal of Gastroenterology and Hepatology 17, S146-S154
CrossRef51
Peter L.M. Jansen. (2002) Liver disease in the elderly. Best Practice & Research Clinical Gastroenterology 16:1, 149-158
CrossRef52
Vincent Di Martino, Thierry Thevenot, Nathalie Boyer, Dominique Cazals-Hatem, Claude Degott, Dominique Valla, Patrick Marcellin. (2002) HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 16:3, 441-445
CrossRef53
Evangelista Sagnelli, Nicola Coppola, Carlo Scolastico, Anna Rita Mogavero, Maria Stanzione, Pietro Filippini, Francesca Maria Felaco, Felice Piccinino. (2001) Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. Journal of Medical Virology 65:4, 681-687
CrossRef54
A Pár. (2001) Therapy for chronic hepatitis C. Journal of Physiology-Paris 95:1-6, 399-405
CrossRef55
Hidenori Toyoda, Takashi Kumada, Takashi Honda, Kazuhiko Hayashi, Yoshiaki Katano, Isao Nakano, Tetsuo Hayakawa, Yoshihide Fukuda. (2001) Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C1. Journal of Gastroenterology and Hepatology 16:10, 1131-1137
CrossRef56
E. Beth Devine, Kris V. Kowdley, David L. Veenstra, Sean D. Sullivan. (2001) Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications. Value in Health 4:5, 376-384
CrossRef57
Mois
CrossRef58
Peter Ferenci, Rudolf Stauber, Petra Steindl-Munda, Michael Gschwantler, Peter Fickert, Christian Datz, Christian M??ller, Franz Hackl, Wolfgang Rainer, Thomas Watkins-Riedel, Werner Lin, G??nter J. Krejs, Alfred Gangl. (2001) Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. European Journal of Gastroenterology & Hepatology 13:6, 699-705
CrossRef59
L. Mazzoran, F. Zorat, L. Chemello, L.S. Crocè, I. Rigato, L. Cavalletto, E. Bernardinello, C. Tiribelli, A. Alberti, G. Pozzato. (2001) Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. Digestive and Liver Disease 33:4, 347-352
CrossRef60
Edoardo Giannini, Alberto Fasoli, Federica Botta, Emanuela Testa, Paola Romagnoli, Paola Ceppa, Roberto Testa. (2001) Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: A functional study. Journal of Gastroenterology and Hepatology 16:4, 399-405
CrossRef61
Giorgio Saracco, Alessia Ciancio, Valeria Ghisetti, Giuseppe Rocca, Giuseppe Cariti, Massimo Andreoni, Marco Tabone, Luigi Roffi, Guido Calleri, Marco Ballar??, Natalia Terreni, Massimo Sartori, Gian Franco Tappero, Antonio Traverso, Antonio Poggio, Annamaria Orani, Giovanni Maggi, Angelo Di Napoli, Arrigo Arrigoni, Mario Rizzetto. (2001) Treatment with interferon-??2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. European Journal of Gastroenterology & Hepatology 13:2, 149-155
CrossRef62
Mitchell L.Shiffman. (2001) Pegylated interferons: What role will they play in the treatment of chronic hepatitis c?. Current Gastroenterology Reports 3:1, 30-37
CrossRef63
Anne Gervais, Nathalie Boyer, Patrick Marcellin. (2001) Tolerability of Treatments for Viral Hepatitis. Drug Safety 24:5, 375-384
CrossRef64
Ke-Qin Hu, John M. Vierling, Allan G. Redeker. (2001) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis 8:1, 1-18
CrossRef65
Murat Gursoy, G. Gur, H. Arslan, N. Ozdemir, S. Boyacioglu. (2001) Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. Journal of Viral Hepatitis 8:1, 70-77
CrossRef66
T. Thevenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, T. Poynard. (2001) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. Journal of Viral Hepatitis 8:1, 48-62
CrossRef67
Delia Menozzi, Troy Udulutch, Augusto E. Llosa, Susan A. Galel. (2000) HCV lookback in the United States:effectiveness of an extended lookback program. Transfusion 40:11, 1393-1398
CrossRef68
H. Toyoda, T. Kumada, A. Tokuda, Y. Horiguchi, H. Nakano, T. Honda, S. Nakano, K. Hayashi, Y. Katano, I. Nakano, T. Hayakawa, D. Nishimura, K. Kato, K. Imada, M. Imoto, Y. Fukuda, . (2000) Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. Journal of Viral Hepatitis 7:6, 414-419
CrossRef69
Laura Benson, Alice Birkel, Linda Caldwell, Valerie Stafford-Fox, Beverley Casarico. (2000) Advances in the Treatment of Hepatitis C: Combination Antiviral Therapy With Interferon alfa-2b and Ribavirin. Journal of the American Academy of Nurse Practitioners 12:9, 364-373
CrossRef70
Sanjay Ramrakhiani, Bruce R. Bacon. (2000) HEPATOLOGY IN THE NEW MILLENNIUM. Medical Clinics of North America 84:5, 1085-1105
CrossRef71
P. Colombatto, M. Baldi, F. Oliveri, A. Randone, F. Bonino, M.R. Brunetto. (2000) Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study. Digestive and Liver Disease 32:3, 211-216
CrossRef72
Berwyn E. Clarke. (2000) New drugs for hepatitis C virus (HCV). Best Practice & Research Clinical Gastroenterology 14:2, 293-305
CrossRef73
G.R Foster, H.C Thomas. (2000) Therapeutic options for HCV—management of the infected individual. Best Practice & Research Clinical Gastroenterology 14:2, 255-264
CrossRef74
David R. Nelson, Gregory Y. Lauwers, Johnson Y.N. Lau, Gary L. Davis. (2000) Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders. Gastroenterology 118:4, 655-660
CrossRef75
Lo Iacono, Castro, Diago, Moreno, Fernandez-Bermejo, Vega, Garcia, Carbonell, Sanz, Borque, Garcia-Buey, Garcia-Monzon, Pedreira, Moreno-Otero. (2000) Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Alimentary Pharmacology and Therapeutics 14:4, 463-469
CrossRef76
Steedman A. Sarbah, Zobair M. Younossi. (2000) Hepatitis C. Journal of Clinical Gastroenterology 30:2, 125-143
CrossRef77
Thierry Poynard, John McHutchison, Zachary Goodman, Mei-Hsiu Ling, Janice Albrecht. (2000) Is an ?
CrossRef78
Mathurin, Thibault, Kadidja, Ganne-Carrié, Moussalli, El Younsi, Di Martino, Lunel, Charlotte, Vidaud, Opolon, Poynard. (2000) Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. Journal of Viral Hepatitis 7:1, 15-22
CrossRef79
Henry David Abraham, Silvia Degli-Esposti, Louis Marino. (1999) Seroprevalence of Hepatitis C in a Sample of Middle Class Substance Abusers. Journal of Addictive Diseases 18:4, 77-87
CrossRef80
Andreas Ambrosch, Wolfgang König. (1999) Charakteristika des Hepatitis-C-Virus und virale Prädiktoren der therapeutischen Intervention. Medizinische Klinik 94:11, 626-632
CrossRef81
Mitchell L. Shiffman, Charlotte M. Hofmann, Melissa J. Contos, Velimir A. Luketic, Arun J. Sanyal, Richard K. Sterling, Andrea Ferreira-Gonzalez, A.Scott Mills, Carlton Garret. (1999) A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117:5, 1164-1172
CrossRef82
Roberts. (1999) The economic aspects of hepatitis C - implications for haemophilia. Haemophilia 5:6, 402-409
CrossRef83
Eishiro Mizukoshi, Shuichi Kaneko, Kyosuke Kaji, Shuichi Terasaki, Eiki Matsushita, Masahiro Muraguchi, Yasukazu Ohmoto, Kenichi Kobayashi. (1999) Serum levels of soluble interferon alfa/beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 30:5, 1325-1331
CrossRef84
Fabris, Tositti, Negro, Marranconi, Infantolino, Rassu, De Lalla. (1999) Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Alimentary Pharmacology and Therapeutics 13:10, 1329-1334
CrossRef85
Yves Benhamou, Marie Bochet, Vincent Di Martino, Frederic Charlotte, Felipe Azria, Anne Coutellier, Michel Vidaud, Fran
CrossRef86
Vogt, Manfred, Lang, Thomas, Frösner, Gert, Klingler, ChristianeSendl, Anna F., Zeller, AnitaWiebecke, Baldur, Langer, Barbara, Meisner, Hans, Hess, John, . (1999) Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. New England Journal of Medicine 341:12, 866-870
Full Text87
E. Verastegui-Aviles, A. Mohar, A. Mota, A. Guadarrama, J. De La Garza-Salazar. (1999) Combination of radiation therapy and interferon alpha-2b in patients with advanced cervical carcinoma: a pilot study. International Journal of Gynecological Cancer 9:5, 401-405
CrossRef88
K. Rajender Reddy, Jay H. Hoofnagle, Myron J. Tong, William M. Lee, Paul Pockros, E. Jenny Heathcote, Donald Albert, Tenshang Joh. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 30:3, 787-793
CrossRef89
T. Poynard, V. Daurat, S. Chevret, J. Moussalli, F. Degos, F. Bailly, E. Borotto, C. Buffet, I. Bartolomei-Portal, J. P. Richardet, G. Riachi, Y. Calmus, C. Bréchot, M. Vidaud, M. Olivi, P. Bedossa, P. Chaumet Riffaud, C. Chastang. (1999) A short induction regimen of interferon-α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. Journal of Viral Hepatitis 6:5, 381-386
CrossRef90
Javier Salmerón, Angela Ruiz-Extremera, Cristina Torres, Luis Rodríguez-Ramos, Isabel Lavín, Dolores Quintero, Angel Palacios. (1999) Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver International 19:4, 275-280
CrossRef91
E. Jenny Heathcote, Stephen James, Kevin D. Mullen, S. C. Hauser, H. Rosenblate, Donald G. Albert, . (1999) Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. Hepatology 30:2, 562-566
CrossRef92
S. Kakizaki, H. Takagi, T. Yamada, T. Ichikawa, T. Abe, N. Sohara, T. Kosone, M. Kaneko, J. Takezawa, H. Takayama, T. Nagamine, M. Mori. (1999) Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. Journal of Viral Hepatitis 6:4, 315-319
CrossRef93
P. Ferenci, R. Stauber, P. Steindl-Munda, M. Gschwantler, P. Fickert, C. Datz, C. Muller, F. Hackl, W. Rainer, T. Watkins-Riedel, W. Lin. (1999) Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C. Journal of Viral Hepatitis 6:s1, 53-58
CrossRef94
Regino P González-Peralta, George J Galasso, Thierry Poynard, Solko Schalm, Howard C Thomas, Teresa L Wright. (1999) Summary of the first international symposium on viral hepatitis. Antiviral Research 42:2, 77-96
CrossRef95
Lisa Nyberg, Janice Albrecht, Paul Glue, Gianluigi Gianelli, Demetris Zambas, Michael Elliot, A. Conrad, John McHutchison. (1999) Changes in Serum Hepatitis C Virus RNA in Interferon Nonresponders Retreated With Interferon Plus Ribavirin. Journal of Clinical Gastroenterology 28:4, 313-316
CrossRef96
Peter Waldron. (1999) Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia. American Journal of Hematology 61:2, 130-134
CrossRef97
Dominique-Charles Valla, Michele Chevallier, Patrick Marcellin, Jean-Louis Payen, Christian Trepo, Marianne Fonck, Marc Bourliere, Evelyne Boucher, Jean-Philippe Miguet, David Parlier, Catherine Lemonnier, Pierre Opolon. (1999) Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 29:6, 1870-1875
CrossRef98
Michiko Shindo, Arai Ken, Tadao Okuno. (1999) Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 85:9, 1943-1950
CrossRef99
Yasushi Shiratori, Osamu Yokosuka, Ryo Nakata, Masashi Ihori, Katsutaro Hirota, Tetsuro Katamoto, Tadao Unuma, Ken'ichi Okano, Yusei Ikeda, Masanori Hirano, Tateo Kawase, Susumu Takano, Kazunori Matsumoto, Yasuo Ohashi, Masao Omata. (1999) Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 29:5, 1573-1580
CrossRef100
Carmen Vandelli, Francesco Renzo, Hans Bertram Braun, Sergio Tisminetzky, Marie Albrecht, Marisa De Palma, Andrea Ranzi, Giuseppe Di Marco, Tommaso Stroffolini, Francesco Baralle, Ezio Ventura, Gerd Michel. (1999) Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. Journal of Medical Virology 58:1, 26-34
CrossRef101
Kenny-Walsh, Elizabeth, . (1999) Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin. New England Journal of Medicine 340:16, 1228-1233
Full Text102
J.G. McHutchison, L.M. Blatt, R. Ponnudurai, K. Goodarzi, J. Russell, A. Conrad. (1999) Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection. Journal of Medical Virology 57:4, 351-355
CrossRef103
Vincent Soriano, Rafael Rodríguez-Rosado, Javier García-Samaniego. (1999) Management of chronic hepatitis C in HIV-infected patients. AIDS 13:5, 539-546
CrossRef104
E J Bini, E H Weinshel. (1999) Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C.. Mayo Clinic Proceedings 74:4, 367-370
CrossRef105
Calogero Camma, Marco Giunta, Giovanbattista Pinzello, Alberto Morabito, Paolo Verderio, Luigi Pagliaro. (1999) Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. The American Journal of Gastroenterology 94:3, 581-595
CrossRef106
Gary L. Davis. (1999) Treatment of chronic hepatitis C: Impact of combination therapy. Current Gastroenterology Reports 1:1, 9-14
CrossRef107
Rodolphe Sobesky, Philippe Mathurin, Frederic Charlotte, Joseph Moussalli, Martine Olivi, Michel Vidaud, Vlad Ratziu, Pierre Opolon, Thierry Poynard. (1999) Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 116:2, 378-386
CrossRef108
Yasushi Shiratori, Naoya Kato, Haruhiko Yoshida, Fumio Imazeki, Ken’ichi Okano, Osamu Yokosuka, Masao Omata. (1999) How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C?. Journal of Gastroenterology and Hepatology 14:1, 79-84
CrossRef109
FF Poordad, RG Gish. (1999) Evolving therapies for the treatment of viral hepatitis. Expert Opinion on Emerging Drugs 4:1, 15-34
CrossRef110
Jean-Louis Payen, Jacques Izopet, Virginie Galindo-Migeot, Val
CrossRef111
McHutchison, John G., Gordon, Stuart C., Schiff, Eugene R., Shiffman, Mitchell L., Lee, William M., Rustgi, Vinod K., Goodman, Zachary D., Ling, Mei-Hsiu, Cort, Susannah, Albrecht, Janice K., . (1998) Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. New England Journal of Medicine 339:21, 1485-1492
Full Text112
Davis, Gary L., Esteban-Mur, Rafael, Rustgi, Vinod, Hoefs, John, Gordon, Stuart C., Trepo, Christian, Shiffman, Mitchell L., Zeuzem, Stefan, Craxi, Antonio, Ling, Mei-Hsiu, Albrecht, Janice, . (1998) Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. New England Journal of Medicine 339:21, 1493-1499
Full Text113
Eishiro Mizukoshi, Shuichi Kaneko, Masayuki Yanagi, Hideki Ohno, Kyosuke Kaji, Shuichi Terasaki, Atsushi Shimoda, Eiki Matsushita, Kenichi Kobayashi. (1998) Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. Journal of Medical Virology 56:3, 217-223
CrossRef114
Markus Peck-Radosavljevic, Martina Wichlas, Johann Pidlich, Paul Sims, Gloria Meng, Johannes Zacherl, Shaily Garg, Christian Datz, Alfred Gangl, Peter Ferenci. (1998) Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 28:5, 1424-1429
CrossRef115
Thierry Poynard, Patrick Marcellin, Samuel S Lee, Christian Niederau, Gerald S Minuk, Gaetano Ideo, Vincent Bain, Jenny Heathcote, Stefan Zeuzem, Christian Trepo, Janice Albrecht. (1998) Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet 352:9138, 1426-1432
CrossRef116
G. L. Davis, J. R. Beck, G. Farrell, T. Poynard. (1998) Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. Journal of Viral Hepatitis 5:5, 313-321
CrossRef117
G. M. DUSHEIKO. (1998) Therapy for chronic hepatitis B and C infection in haemophilia. Haemophilia 4:4, 577-586
CrossRef118
Giuseppe Montalto, Silvio Tripi, Antonino Cartabellotta, Marcella Fulco, Maurizio Soresi, Giuseppa Gaetano, Antonio Carroccio, Massimo Levrero. (1998) Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. The American Journal of Gastroenterology 93:6, 950-953
CrossRef119
Thierry Poynard, Pierre Opolon. (1998) Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?. Hepatology 27:5, 1443-1444
CrossRef120
F. Zoulim, J. Haem, S. Si Ahmed, P. Chossegros, F. Habersetzer, M. Chevallier, F. Bailly, C. Trepo. (1998) Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. Journal of Viral Hepatitis 5:3, 193-198
CrossRef121
Clifford A. Brass. (1998) Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection. Clinical Therapeutics 20:3, 388-397
CrossRef122
Kenneth E. Sherman, Maria Sjogren, Robin L. Creager, Melissa A. Damiano, Stephen Freeman, Scot Lewey, Dirk Davis, Spencer Root, Frederick L. Weber, Kamal G. Ishak, Zachary D. Goodman. (1998) Combination therapy with thymosin ?1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology 27:4, 1128-1135
CrossRef123
Geoffrey C. Farrell, Bruce R. Bacon, Robert D. Goldin, . (1998) Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial. Hepatology 27:4, 1121-1127
CrossRef124
Philippe Mathurin, Joseph Moussalli, Jean-Fran
CrossRef125
Manal F. Abdelmalek, M. Edwyn Harrison, John B. Gross, John J. Poterucha, Andrea A. Gossard, James R. Spivey, Jorge Rakela, Keith D. Lindor. (1998) Treatment of Chronic Hepatitis C With Interferon With or Without Ursodeoxycholic Acid. Journal of Clinical Gastroenterology 26:2, 130-134
CrossRef126
Miriam J. Alter, Eric E. Mast, Linda A. Moyer, Harold S. Margolis. (1998) HEPATITIS C. Infectious Disease Clinics of North America 12:1, 13-26
CrossRef127
Wolfgang Fischbach, Volker Groß, Jürgen Schölmerich, Christian Ell, Peter Layer, Wolfgang E. Fleig. (1998) Update Gastroenterologie 1997—Teil II. Medizinische Klinik 93:3, 146-164
CrossRef128
Tatehiro Kagawa, Katsumi Hosoi, Shinji Takashimizu, Kazuya Kawazoe, Kaori Mochizuki, Mitsuru Wasada, Naruhiko Nagata, Junzo Uchiyama, Atsushi Nakano, Yasuhiro Nishizaki, Norihito Watanabe, Shohei Matsuzaki. (1998) Comparison of Two Interferon Alfa Treatment Regimens Characterized by an Early Virological Response in Patients With Chronic Hepatitis C. The American Journal of Gastroenterology 93:2, 192-196
CrossRef129
Olle Reichard, Gunnar Norkrans, Aril Frydén, Jean-Henrik Braconier, Anders Sönnerborg, Ola Weiland. (1998) Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Lancet 351:9096, 83-87
CrossRef130
Mariano Malaguarnera, Ignazio Di Fazio, Salvatore Restuccia, Giovanni Pistone, Nunzio Restuccia, Barbara Adriana Trovato. (1998) Efficacy of different schedules in the management of chronic hepatitis C with interferon-oc. Annals of Medicine 30:2, 213-217
CrossRef131
Howe Sim, Colina Yim, Mel Krajden, Jenny Heathcote. (1998) Durability of Serological Remission in Chronic Hepatitis C Treated With Interferon-Alpha-2B. The American Journal of Gastroenterology 93:1, 39-43
CrossRef132
D. Ouzan, G. Babany, D. Valla, P. Opolon. (1998) Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. Journal of Viral Hepatitis 5:1, 53-59
CrossRef133
Adrian M Di Bisceglie. (1998) Hepatitis C. The Lancet 351:9099, 351-355
CrossRef134
G. Montalto, M. Soresi, A. Carroccio, G. Anastasi, P. Campagna, F. Vasile, L. Di Prima, A. Cartabellotta, L. Giannitrapani, M. Fulco. (1998) Comparative Responses to Three Different Types of Interferon-α in Patients with Chronic Hepatitis C. Current Medical Research and Opinion 14:4, 235-241
CrossRef135
S. Mauss, H. Klinker, A. Ulmer, R. Willers, B. Weißbrich, H. Albrecht, D. Häussinger, H. Jablonowski. (1998) Response to treatment of chronic hepatitis C with interferon α in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 26:1, 16-19
CrossRef136
Evangelos A. Akriviadis, Ioannis Xanthakis, Christina Navrozidou, Anastassios Papadopoulos. (1997) Prevalence of Cryoglobulinemia in Chronic Hepatitis C Virus Infection and Response to Treatment With Interferon-α. Journal of Clinical Gastroenterology 25:4, 612-618
CrossRef137
W. G. E. Cooksley, F. J. Dudley, K. Watson. (1997) Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-α 2a. Journal of Viral Hepatitis 4:s2, 75-78
CrossRef138
H. C. Thomas, J. A. Waters. (1997) Future approaches to treatment of chronic hepatitis B and hepatitis C infection. Journal of Viral Hepatitis 4:s2, 92-97
CrossRef139
W. G. E. Cooksley. (1997) Interferon treatment of chronic hepatitis C with cirrhosis. Journal of Viral Hepatitis 4:s1, 85-88
CrossRef140
J. M. Vierling, F. G. Villamil, S. E. Rojter, K. B. Camacho, D. E. Goldman. (1997) Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. Journal of Viral Hepatitis 4:s1, 117-124
CrossRef141
Stephen D.H.P. Malnick, Hemda Schmilovitz-Weiss. (1997) Editorial: Interferon Therapy for Chronic HCV Hepatitis: Trick or Treat?. Journal of Clinical Gastroenterology 25:1, 310-313
CrossRef142
Hugo R. Rosen. (1997) Acquisition of hepatitis C by a conjunctival splash. American Journal of Infection Control 25:3, 242-247
CrossRef143
Jonathan C. L. Booth, Graham R. Foster, Tanya Levine, Howard C. Thomas, Robert D. Goldin. (1997) The relationship of histology to genotype in chronic HCV infection. Liver 17:3, 144-151
CrossRef144
SHINICHI KAKUMU, TOSHIYUKI AIYAMA, AKIHIKO OKUMURA, KAZUO IWATA, TETSUYA ISHIKAWA, KENTARO YOSHIOKA. (1997) Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. Journal of Gastroenterology and Hepatology 12:6, 468-472
CrossRef145
C Trépo, P Merle, F Bailly. (1997) Traitements des hépatites C. La Revue de Médecine Interne 18, s72-s75
CrossRef146
Brian J G Pereira, Andrew S Levey. (1997) Hepatitis C virus infection in dialysis and renal transplantation. Kidney International 51:4, 981-999
CrossRef147
Franco Dammacco, Domenico Sansonno. (1997) Mixed cryoglobulinemia as a model of systemic vasculitis. Clinical Reviews in Allergy & Immunology 15:1, 97-119
CrossRef148
Thierry Poynard, Pierre Bedossa, Pierre Opolon. (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet 349:9055, 825-832
CrossRef149
Dominik M. Alscher, J. Christian Bode. (1997) Therapie der Hepatitis C. Medizinische Klinik 92:3, 147-161
CrossRef150
Wood, Alastair J.J., , Hoofnagle, Jay H., Di Bisceglie, Adrian M., . (1997) The Treatment of Chronic Viral Hepatitis. New England Journal of Medicine 336:5, 347-356
Full Text151
Helge Bell, Kjell Hellum, Stig Harthug, Arild Mæland, Ståle Ritland, Bjørn Myrvang, Bent Von Der Lippe, Nils Raknerud, Kjell Skaug, Bjørg-Guri Gutigard, Rolv Skjærven, Linda E. Prescott, Peter Simmonds. (1997) Genotype, Viral Load and Age as Independent Predictors of Treatment Outcome of Interferon-α2a Treatment in Patients with Chronic Hepatitis C. Scandinavian Journal of Infectious Diseases 29:1, 17-22
CrossRef152
Lucile Musset, Pascale Ghillani, Françoise Lunel, Patrice Cacoub, Pascale Cresta, Lionel Frangeul, Michel Rosenheim, Jean-Louis Preud'homme. (1997) Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-α therapy. Immunology Letters 55:1, 41-45
CrossRef153
Vito Di Marco, Oreste Lo Iacono, Calogero Cammà, Piero L. Almasio, Alessandra Vaccaro, Patrizia Fuschi, Marco Giunta, Carmelo Fabiano, Luigi Pagliaro, Antonio Craxì. (1997) A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. Journal of Medical Virology 51:1, 17-24
CrossRef154
Rafael Esteban. (1996) Managing patients on interferon therapy. Digestive Diseases and Sciences 41:S12, 121S-125S
CrossRef155
Thierry Poynard, Vincent Leroy, Philippe Mathurin, Marielle Cohard, Pierre Opolon, Jean Pierre Zarski. (1996) Treatment of chronic hepatitis C by interferon for longer duration than six months. Digestive Diseases and Sciences 41:S12, 99S-102S
CrossRef156
Giorgio Saracco, Mario Rizzetto. (1996) Predictors of response to interferon therapy. Digestive Diseases and Sciences 41:S12, 115S-120S
CrossRef157
Norah A. Terrault. (1996) Treatment of Chronic Hepatitis B and Chronic Hepatitis C. Reviews in Medical Virology 6:4, 215-228
CrossRef158
Peter Ferenci, Rudolf Stauber, Albert Propst, Richard Fiedler, Christian Müller, Michael Gschwantler, Kurt Schütze, Christian Datz, Gerd Judmaier, Wolfgang Vogel, Günther J. Krejs, Alfred Gangl. (1996) Dose increase augments response rate to interferon-α in chronic hepatitis C. Digestive Diseases and Sciences 41:S12, 103S-108S
CrossRef159
William S. David, Craig Peine, Peter Schlesinger, Stephen A. Smith. (1996) Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. Muscle & Nerve 19:12, 1596-1602
CrossRef160
Geoffrey C. Farrell. (1996) Two years versus six months of interferon therapy for chronic hepatitis C. Digestive Diseases and Sciences 41:S12, 93S-98S
CrossRef161
Hideyuki Nomura, Youichi Kimura, Hitoshi Tada, Chizuko Hisano, Chika Morita, Osamu Okamoto, Genji Shiraishi, Seizaburo Kashiwagi. (1996) Predictive Factors of a Response to Interferon Therapy in Chronic Hepatitis C. Journal of Clinical Gastroenterology 23:3, 185-190
CrossRef162
Heather Preston, Teresa L Wright. (1996) Interferon therapy for hepatitis C. The Lancet 348:9033, 973-974
CrossRef163
D.D. Eckels, P. Flomenberg, J.C. Gill. (1996) Hepatitis C virus: models of immunopathogenesis and prophylaxis. Transfusion 36:9, 836-844
CrossRef164
GEORGE M. BAHR, PHILIPPE R. POUILLART, LOUIS A. CHEDID. (1996) Enhancement In Vivo of the Antiinflammatory and Antitumor Activities of Type I Interferon by Association with the Synthetic Immunomodulator Murabutide. Journal of Interferon & Cytokine Research 16:4, 297-306
CrossRef165
Gane, Edward J., Portmann, Bernard C., Naoumov, Nikolai V., Smith, Heather M., Underhill, James A., Donaldson, Peter T., Maertens, Geert, Williams, Roger, . (1996) Long-Term Outcome of Hepatitis C Infection after Liver Transplantation. New England Journal of Medicine 334:13, 815-821
Full Text166
Vincent Agnello, Paul L. Romain. (1996) MIXED CRYOGLOBULINEMIA SECONDARY TO HEPATITIS C VIRUS INFECTION. Rheumatic Disease Clinics of North America 22:1, 1-21
CrossRef167
Hugo R. Rosen, Lawrence S. Friedman, Paul Martin. (1996) Hepatitis C and the Renal Transplant Patient. Seminars in Dialysis 9:1, 39-46
CrossRef168
Herbert L. Bonkovsky, Bernard D. Clifford, Lynda J. Smith, Carol Allan, Barbara Banner. (1996) High-dose interferon-α2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. Digestive Diseases and Sciences 41:1, 149-154
CrossRef169
Raymond S. Koff, Leonard B. Seeff. (1995) Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: Promises and limitations. Hepatology 22:6, 1880-1882
CrossRef170
JoséM Sánchez-Tapias, Juan Rodés. (1995) Interferon in chronic hepatitis C. The Lancet 346, S11
CrossRef171
Terrault, Norah, Wright, Teresa, . (1995) Interferon and Hepatitis C. New England Journal of Medicine 332:22, 1509-1511
Full Text
